Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells

Cellular Physiology and Biochemistry

Volumn 26, Issue 4-5, 2010, Pages 647-656

  Monjo, Marta ^a   Rubert, Marina ^a   Ellingsen, Jan Eirik ^b   Lyngstadaas, S Petter ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Bone morphogenetic protein 2 (BMP 2); In vitro; Osteoblast differentiation; Solute carrier (SLC) gene family transporter; Statin

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CARRIER PROTEIN; COLLAGEN TYPE 1; LACTATE DEHYDROGENASE; MESSENGER RNA; MONOCARBOXYLATE TRANSPORTER 1; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PROTEIN SLC22A8; PROTEIN SLCO1A1; PROTEIN SLCO2B1; ROSUVASTATIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; KIDNEY PARENCHYMA; LIVER; MOUSE; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS; RICE STRIPE VIRUS;

EID: 78149431109     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322332     Document Type: Article

References (52)

1. Hamelin BA, Turgeon J: Hydrophilicity/ lipophilicity: Relevance for the pharmacology and clinical effects of hmg-coa reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37.
2. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000;101:207-213.
3. Garrett IR, Gutierrez G, Mundy GR: Statins and bone formation. Curr Pharm Des 2001;7:715-736.
4. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
5. Tandon V, Bano G, Khajuria V, Parihar A, Gupta S: Pleiotropic effects of statins. Indian J Pharmacology 2005;37:77-85.
6. Garrett IR, Mundy GR: The role of statins as potential targets for bone formation. Arthritis Res 2002;4:237-240.
7. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
8. Grasser WA, Baumann AP, Petras SF, Harwood HJ, Jr, Devalaraja R, Renkiewicz R, Baragi V, Thompson DD, Paraklar VM: Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact 2003;3:53-62.
9. Hughes A, Rogers MJ, Idris AI, Crockett JC: A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariec-tomy-induced bone loss in vivo. Calcif Tissue Int 2007;81:403-413.
10. Gonyeau MJ: Statins and osteoporosis: A clinical review. Pharmacotherapy 2005;25:228-243.
11. Jadhav SB, Jain GK: Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol 2006;58:3-18.
12. Koida M, Fukuyama R, Nakamuta H: Osteoporosis requires bone-specific statins. Curr Pharm Des 2004;10:2605-2613.
13. Mundy GR: Statins and their potential for osteoporosis. Bone 2001;29:495-497.
14. Rizzo M, Di Fede G, Mansueto P, Castello F, Carmina E, Rini GB: Statins and osteoporosis: Myth or reality? Minerva Med 2004;95:521-527.
15. Baek KH, Lee WY, Oh KW, Tae HJ, Lee JM, Lee EJ, Han JH, Kang MI, Cha B Y, Lee KW, Son H Y, Kang SK: The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci 2005;20:438-444.
16. Ghosh-Choudhury N, Mandal CC, Choudhury GG: Statin-induced ras activation integrates the phosphatidy-linositol 3-kinase signal to akt and mapk for bone morphogenetic protein-2 expression in osteoblast differentiation. J Biol Chem 2007;282:4983-4993.
17. Maeda T, Matsunuma A, Kawane T, Horiuchi N: Simvastatin promotes oste-oblast differentiation and mineralization in mc3t3-e1 cells. Biochem Biophys Res Commun 2001;280:874-877.
18. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N: Induction of osteoblast differentiation indices by statins in mc3t3-e1 cells. J Cell Biochem 2004;92:458-471.
19. Ruiz-Gaspa S, Nogues X, Enjuanes A, Monllau JC, Blanch J, Carreras R, Mellibovsky L, Grinberg D, Balcells S, Diez-Perez A, Pedro-Botet J: Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and mg-63 cultures. J Cell Biochem 2007;101:1430-1438.
20. Song C, Guo Z, Ma Q, Chen Z, Liu Z, Jia H, Dang G: Simvastatin induces osteob-lastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 2003;308:458-462.
21. Viereck V, Grundker C, Blaschke S, Frosch KH, Schoppet M, Emons G, Hofbauer LC: Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 2005;96:1244-1253.
22. Oxlund H, Andreassen TT: Simvastatin treatment partially prevents ovariec-tomy-induced bone loss while increasing cortical bone formation. Bone 2004;34:609-618.
23. Staal A, Frith JC, French MH, Swartz J, Gungor T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH: The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on hmg-coa reductase activity. J Bone Miner Res 2003;18:88-96.
24. Schachter M: Chemical, pharmaco-kinetic and pharmacodynamic properties of statins: An update. Fundam Clin Phamacol 2005;19(1):117-125.
25. Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y: Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 1992;209:315-319.
26. Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C, Horiuchi S: Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 1992;43:667-670.
27. Sakamoto K, Mikami H, Kimura J: Involvement of organic anion transporting polypeptides in the toxicity of hy-drophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres. Br J Pharmacol 2008;154:1482-1490.
28. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gas-troenterology 2006;130:1793-1806.
29. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T: The organic anion transporter (oatp) family. Drug Metab Pharmacokinet 2004;19:171-179.
30. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (roat3; slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther 2002;300:746-753.
31. Konig J, Seithel A, Gradhand U, Fromm MF: Pharmacogenomics of human oatp transporters. Naunyn Schmiedebergs Arch Pharmacol 2006;372:432-443.
32. Morris ME, Felmlee MA: Overview of the proton-coupled mct (slc16a) family of transporters: Characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J 2008;10:311-321.
33. Cheng X, Maher J, Chen C, Klaassen CD: Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (oatps). Drug Metab Dispos 2005;33:1062-1073.
34. Skoglund B, Forslund C, Aspenberg P: Simvastatin improves fracture healing in mice. J Bone Miner Res 2002;17:2004-2008.
35. Anbinder AL, Junqueira JC, Mancini MN, Balducci I, Rocha RF, Carvalho YR: Influence of simvastatin on bone regeneration of tibial defects and blood cholesterol level in rats. Braz Dent J 2006;17:267-273.
36. Gutierrez GE, Lalka D, Garrett IR, Rossini G, Mundy GR: Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int 2006;17:1033-1042.
37. Ayukawa Y, Okamura A, Koyano K: Simvastatin promotes osteogenesis around titanium implants. Clin Oral Implants Res 2004;15:346-350.
38. Ayukawa Y, Yasukawa E, Moriyama Y, Ogino Y, Wada H, Atsuta I, Koyano K: Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):336-42.
39. Monjo M, Rubert M, Wohlfahrt JC, Ronold HJ, Ellingsen JE, Lyngstadaas SP: In vivo performance of absorbable collagen sponges with rosuvastatin in critical-size cortical bone defects. Acta Biomater 2010;6:1405-1412.
40. Moriyama Y, Ayukawa Y, Ogino Y, Atsuta I, Koyano K: Topical application of statin affects bone healing around implants. Clin Oral Implants Res 2008;19:600-605.
41. Nyan M, Sato D, Oda M, Machida T, Kobayashi H, Nakamura T, Kasugai S: Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect. J Pharmacol Sci 2007;104:384-386.
42. Seto H, Ohba H, Tokunaga K, Hama H, Horibe M, Nagata T: Topical administration of simvastatin recovers alveolar bone loss in rats. J Periodontal Res 2008;43:261-267.
43. Stein D, Lee Y, Schmid MJ, Killpack B, Genrich MA, Narayana N, Marx DB, Cullen DM, Reinhardt RA: Local simvastatin effects on mandibular bone growth and inflammation. J Periodontol 2005;76:1861-1870.
44. Wong RW, Rabie AB: Early healing pattern of statin-induced osteogenesis. Br J Oral Maxillofac Surg 2005;43:46-50.
45. Armitage J: The safety of statins in clinical practice. Lancet 2007;370:1781-1790.
46. Olsson GO: Safety and efficacy of rosuvastatin. Lancet 2004;364:135.
47. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ: Inhibitors of 3-hydroxy-3-methylglutaryl-coa reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004;15:2258-2265.
48. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci \USA 1991;88:3628-3632.
49. Rogers MJ: Statins: Lower lipids and better bones? Nat Med 2000;6:21-23.
50. Sonobe M, Hattori K, Tomita N, Yoshikawa T, Aoki H, Takakura Y, Suguro T: Stimulatory effects of statins on bone marrow-derived mesenchymal stem cells. Study of a new therapeutic agent for fracture. Biomed Mater Eng 2005;15:261-267.
51. Noe J, Portmann R, Brun ME, Funk C: Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (oatp) substrates on oatp1b1, oatp2b1, and oatp1b3. Drug Metab Dispos 2007;35:1308-1314.
52. Tirona RG, Kim RB: Pharmacogenomics of organic anion-transporting polype-ptides (oatp). Adv Drug Deliv Rev 2002;54:1343-1352.